Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW799943X once-daily dose and timing study in persistent bronchial asthma
2004-005058-30Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GW799943X in asthma (5 arms), sponsored by GSK. Primary endpoint: Mean change from baseline in daily trough morning peak expiratory flow. Started Jul 2005; status: completed.
02
Drugs
GW799943X
03
Conditions
asthma
Beyond the preview
Go deeper on 2004-005058-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005058-30.